

Anat Fisher

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2265322/publications.pdf>

Version: 2024-02-01

26
papers

438
citations

933264

10
h-index

752573

20
g-index

27
all docs

27
docs citations

27
times ranked

607
citing authors

#	ARTICLE	IF	CITATIONS
1	Sodiumâ€“Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis. <i>Annals of Internal Medicine</i> , 2020, 173, 417-425.	2.0	97
2	Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study. <i>BMJ, The</i> , 2020, 370, m3342.	3.0	70
3	Clinical Research Needs for the Management of Chronic Rhinosinusitis with Nasal Polyps in the New Era of Biologics: A National Institute of Allergy and Infectious Diseases Workshop. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 1532-1549.e1.	2.0	38
4	Comparative Persistence of the TNF Antagonists in Rheumatoid Arthritis â€“ A Population-Based Cohort Study. <i>PLoS ONE</i> , 2014, 9, e105193.	1.1	33
5	Sodiumâ€“Glucose Cotransporter 2 Inhibitors and the Risk of Below-Knee Amputation: A Multicenter Observational Study. <i>Diabetes Care</i> , 2020, 43, 2444-2452.	4.3	26
6	Fluoroquinolone use for uncomplicated urinary tract infections in women: a retrospective cohort study. <i>Clinical Microbiology and Infection</i> , 2020, 26, 613-618.	2.8	20
7	Tolerability of Cholinesterase Inhibitors: A Population-Based Study of Persistence, Adherence, and Switching. <i>Drugs and Aging</i> , 2017, 34, 221-231.	1.3	17
8	Comparison of Pregnancy Outcomes of Patients Treated With Ondansetron vs Alternative Antiemetic Medications in a Multinational, Population-Based Cohort. <i>JAMA Network Open</i> , 2021, 4, e215329.	2.8	17
9	Weight and inflammation are the major determinants of vascular dysfunction in the aortae of db/db mice. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2011, 383, 483-492.	1.4	13
10	Sodiumâ€“glucose coâ€“transporterâ€“2 inhibitors and the risk of urosepsis: A multiâ€“site, prevalent newâ€“user cohort study. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1648-1658.	2.2	13
11	Cholinesterase Inhibitor Utilization: The Impact of Provincial Drug Policy on Discontinuation. <i>Value in Health</i> , 2016, 19, 688-696.	0.1	11
12	Comparative effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists in nonvalvular atrial fibrillation: a Canadian multicentre observational cohort study. <i>CMAJ Open</i> , 2020, 8, E877-E886.	1.1	10
13	Prescriber preference for a particular tumour necrosis factor antagonist drug and treatment discontinuation: population-based cohort. <i>BMJ Open</i> , 2014, 4, e005532-e005532.	0.8	9
14	Tofacitinib Persistence in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study. <i>Journal of Rheumatology</i> , 2021, 48, 16-24.	1.0	9
15	Effectiveness and safety among direct oral anticoagulants in nonvalvular atrial fibrillation: A multiâ€“database cohort study with metaâ€“analysis. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2589-2601.	1.1	8
16	Validity of an algorithm to identify cardiovascular deaths from administrative health records: a multi-database population-based cohort study. <i>BMC Health Services Research</i> , 2021, 21, 758.	0.9	8
17	Rapid monitoring of health services utilization following a shift in coverage from brand name to biosimilar drugs in British Columbiaâ€“An interim report. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 803-810.	0.9	6
18	Heterogeneity in Comparisons of Discontinuation of Tumor Necrosis Factor Antagonists in Rheumatoid Arthritis - A Meta-Analysis. <i>PLoS ONE</i> , 2016, 11, e0168005.	1.1	6

#	ARTICLE	IF	CITATIONS
19	Policy-induced selection bias in pharmacoepidemiology: The example of coverage for Alzheimer's medications in British Columbia. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 1067-1076.	0.9	5
20	Comparative Effectiveness Of Fluoroquinolone Antibiotic Use In Uncomplicated Acute Exacerbations Of COPD: A Multi-Cohort Study. <i>International Journal of COPD</i> , 2019, Volume 14, 2939-2946.	0.9	5
21	A rapid monitoring plan following a shift in coverage from brand name to biosimilar drugs for rheumatoid arthritis in British Columbia. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 796-802.	0.9	4
22	Rapid monitoring of health services use following a policy to switch patients from originator to biosimilar etanercept—a cohort study in British Columbia. <i>BMC Rheumatology</i> , 2022, 6, 5.	0.6	4
23	Off-label postpartum use of domperidone in Canada: a multidatabase cohort study. <i>CMAJ Open</i> , 2021, 9, E500-E509.	1.1	3
24	Mandatory nonmedical switching from originator to biosimilar infliximab in patients with inflammatory arthritis and psoriasis in British Columbia: a cohort study. <i>CMAJ Open</i> , 2022, 10, E109-E118.	1.1	3
25	The Impact of Mandatory Nonmedical Switching From Originator to Biosimilar Insulin Glargine. <i>Clinical Therapeutics</i> , 2022, 44, 957-970.e12.	1.1	3
26	Impact of using concomitant conventional DMARDs on adherence to biologic DMARD treatment in rheumatoid arthritis: Multi-centre, population-based cohort study. <i>Seminars in Arthritis and Rheumatism</i> , 2021, , .	1.6	0